We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteome Systems and PHIMR Signs Agreement to Develop Ovarian Cancer Diagnostic Test
News

Proteome Systems and PHIMR Signs Agreement to Develop Ovarian Cancer Diagnostic Test

Proteome Systems and PHIMR Signs Agreement to Develop Ovarian Cancer Diagnostic Test
News

Proteome Systems and PHIMR Signs Agreement to Develop Ovarian Cancer Diagnostic Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteome Systems and PHIMR Signs Agreement to Develop Ovarian Cancer Diagnostic Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteome Systems has announced collaboration with PHIMR (Prince Henry’s Institute Medical Research) to combine their IP and expertise in ovarian cancer for the discovery and development of diagnostic markers.

Proteome Systems has discovered and patented markers for epithelial ovarian cancer using its proteomic and glycoproteomic technology platforms.

The company is actively seeking partnerships with academic and clinical groups with expertise in ovarian cancer to further expand its portfolio of ovarian cancer markers and clinically evaluate these for the development of a diagnostic test.

Associate Professor David Robertson leads the team at PHIMR that has previously developed a test to diagnose ovarian cancer (Robertson et al., 2002; Robertson and Oehler, 2005).

The test is useful for initial diagnosis and monitoring recurrence of the disease in post-menopausal women, but it does not have the required specificity and sensitivity for application to diagnosis of early stage disease.

PHIMR bring complementary technology in proteomics and reproductive biology, as well as clinical expertise in ovarian cancer, for the discovery and evaluation of diagnostic markers.

Dr Jenny Harry, Deputy CEO and Head of Diagnostics at Proteome Systems said, “She is delighted to be working with an outstanding team of scientists at PHIMR who also have strong commercial focus.”

“The identification of diagnostic markers for the early stages of ovarian cancer will provide the basis for the development of a screening test and lead to a better prognosis for women with this disease.”

“Women would be able to regularly screen for ovarian cancer as is currently possible for breast and cervical cancers.”

Advertisement